CME/CE

Faculty: Prem S. Subramanian, MD, PhD

Faculty: Andrea Lora Kossler, MD, FACS

Join our experts as they explore why clinical activity scores (CAS) alone often fail to capture the full impact of thyroid eye disease (TED) severity and what tools can help align treatment with patients’ true disease burden. See how emerging TED therapies and the latest clinical trial data are reshaping patient-centered care. Discover how our experts streamline clinic workflows, reduce infusion burden, and coordinate care to improve patient outcomes.

Faculty: Prem S. Subramanian, MD, PhD

Faculty: Kimberly Cockerham, MD

Join our experts as they explore why clinical activity scores (CAS) alone often fail to capture the full impact of thyroid eye disease (TED) severity and what tools can help align treatment with patients’ true disease burden. See how emerging TED therapies and the latest clinical trial data are reshaping patient-centered care. Discover how our experts streamline clinic workflows, reduce infusion burden, and coordinate care to improve patient outcomes.

Faculty: Prem S. Subramanian, MD, PhD

Faculty: Andrea Lora Kossler, MD, FACS

Join our experts as they explore why clinical activity scores (CAS) alone often fail to capture the full impact of thyroid eye disease (TED) severity and what tools can help align treatment with patients’ true disease burden. See how emerging TED therapies and the latest clinical trial data are reshaping patient-centered care. Discover how our experts streamline clinic workflows, reduce infusion burden, and coordinate care to improve patient outcomes.

Faculty: Andrea Lora Kossler, MD, FACS

Faculty: Kimberly Cockerham, MD

Join our experts as they explore why clinical activity scores (CAS) alone often fail to capture the full impact of thyroid eye disease (TED) severity and what tools can help align treatment with patients’ true disease burden. See how emerging TED therapies and the latest clinical trial data are reshaping patient-centered care. Discover how our experts streamline clinic workflows, reduce infusion burden, and coordinate care to improve patient outcomes.

Faculty: Prem S. Subramanian, MD, PhD

Faculty: Kimberly Cockerham, MD

Join our experts as they explore why clinical activity scores (CAS) alone often fail to capture the full impact of thyroid eye disease (TED) severity and what tools can help align treatment with patients’ true disease burden. See how emerging TED therapies and the latest clinical trial data are reshaping patient-centered care. Discover how our experts streamline clinic workflows, reduce infusion burden, and coordinate care to improve patient outcomes.

Faculty: Neeraj Agarwal, MD, FASCO

Faculty: Rana McKay, MD

In this podcast, Drs. Rana McKay and Neeraj Agarwal discuss risk stratification in localized and nonmetastatic castration-sensitive prostate cancer (CSPC), highlighting the clinical and imaging factors used to identify patients at increased risk of recurrence and disease progression. The faculty examine the evolving role of treatment intensification, including androgen deprivation therapy–based combination approaches and the earlier use of androgen receptor pathway inhibitors in patients with high-risk disease. They also explore how advances in imaging, multidisciplinary care, and emerging clinical evidence are shaping treatment selection and timing. In addition, the discussion addresses practical considerations for managing adverse events associated with intensified therapy and incorporating these strategies into clinical practice.

Faculty: Neeraj Agarwal, MD, FASCO

Faculty: Rana McKay, MD

This podcast explores the evolving role of molecular profiling and biomarker testing in metastatic castration-sensitive prostate cancer (mCSPC). Drs. Neeraj Agarwal and Rana McKay discuss the clinical significance of PTEN loss and other genomic alterations, their prognostic implications, and how they may inform treatment selection. The conversation reviews emerging data on targeted therapeutic strategies and the integration of precision medicine earlier in the disease course. Practical considerations for incorporating biomarker assessment into clinical decision-making are also examined.

Faculty: Lina Badimón, MD, PhD

Faculty: Michelle O’Donoghue, MD, MPH

Faculty: Erin Michos, MD, MHS

Faculty: Pam R. Taub, MD

A new modular CME-accredited program designed to support clinicians in translating evolving lipid guidelines into everyday practice. Delivered as a 60-minute webcast, divided into chapters for convenience, it integrates U.S. and international perspectives and focuses on equitable cardiovascular care. The course highlights women-specific cardiovascular risk modifiers, including reproductive and hormonal factors that are often under-recognized in risk assessment. It also emphasizes practical, multidisciplinary approaches to improving lipid management outcomes across diverse health systems.

To learn more about Women As One, please click here for additional information.

Faculty: Jorge Plutzky, MD

Faculty: Bradley Eilerman, MD, MHI

With our current understanding of how prevalent hypercortisolism is in patients with difficult-to-manage cardiometabolic disease, the focus shifts to what might clinicians do differently in practice? Which patients should healthcare providers screen, and what straightforward testing methods can be used to detect and confirm hypercortisolism with confidence? Once identified, how might earlier intervention alter the course of disease progression?

Faculty: Alireza Atri, MD, PhD

Faculty: Raymond Scott Turner, MD, PhD

Faculty: Dani Cabral, MD

In this activity, Dr. Alireza Atri and Dr. Scott Turner discuss the evolving role of subcutaneous anti-amyloid monoclonal antibody therapy in early Alzheimer disease. The conversation compares intravenous and subcutaneous administration and focuses on maintenance dosing after 18 months of IV therapy, practical implications for patients and care partners, and the potential impact on infusion-center burden and treatment access. Dr. Dani Cabral then speaks with a patient living with Alzheimer’s disease, who shares his perspective on using the subcutaneous formulation in the broader context of disease-modifying treatment and long-term management.